Drug Use Investigation for TYKERB Tablet (All Case Investigation)

• Status: Completed
• Trial end date: 2017-03-13
• Target enrollment: 0
• Participant gender: All

Summary

Data on the safety and efficacy of TYKERB shall be collected from the patients in order to grasp the actual conditions of post-marketing use and assess background information on the patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Lapatinib

Criteria

Inclusion Criteria:

• Patients with HER2 overexpressing inoperable or recurrent breast cancer

Exclusion Criteria:

• Patients with hypersensitivity to lapatinib or any components

• Pregnant women and women suspected of being pregnant